Effective treatment with fucoidin for perinatal hypoxic-ischemic encephalopathy in rats.

Leukocyte-endothelial adhesion is a key step to initiate post-ischemic reperfusion injury in many organs. In this study, we found that the expressions of P-selectin mRNA and protein were increased in the ipsilateral hemisphere with a peak at 8 h after hypoxia-ischemia in immature brain. Such temporal profiles of P-selectin expression followed by hypoxia-ischemia are consistent with a role in the subsequent brain injury. Because fucoidin is known to inhibit P/L-selectin mediated leukocyte adhesion, we examined whether the treatment of fucoidin attenuates hypoxia-ischemia-induced neural damages. Treatment with fucoidin exhibited a substantial neuroprotective effect in a dose-dependent manner and inhibited the leukocyte adhesion significantly, as revealed by myeloperoxidase activity. These results suggest that anti-adhesion strategy may be an effective therapeutic application for the perinatal hypoxic-ischemic encephalopathy.

The induction of BDNF and c-fos mRNA in the hippocampal formation after febrile seizures.

In this study we investigated the expression of brain-derived neurotrophic factor (BDNF) and c-fos mRNA in the hippocampal formation after febrile seizures (FSs) with in situ hybridization histochemistry using riboprobes. The induction of BDNF mRNA was firstly observed in the dentate gyrus at 30 min after FSs. The expression in the dentate gyrus peaked at 3 h and returned to basal level at 24 h. It was also observed in the CA3 of hippocampus from 2 to 3 h. The induction of c-fos mRNA was observed in the dentate gyrus at 30 min and 1 h. These observations suggest that BDNF and c-fos are the genes whose expression can be altered by FSs and might be related to pathologic alterations after FSs.

Platelet-activating factor antagonist BN 50730 attenuates hypoxic-ischemic brain injury in neonatal rats.

Platelet-activating factor (PAF) is a lipid derived from breakdown of cell membranes that is postulated to be a mediator of cerebral ischemic injury. PAF regulates CNS gene transcription via intracellular binding sites. To test the hypothesis that PAF mediates CNS injury in part by modulating gene transcription, we evaluated the neuroprotective efficacy of the drug BN 50730, an antagonist of the intracellular (microsomal) CNS PAF binding site, in the neonatal rat model of unilateral cerebral hypoxia-ischemia. Seven-day-old rats underwent right carotid ligation followed by a 2.5-h exposure to 8% O(2), and were then treated with BN 50730 (2.5 or 25 mg/kg per dose) or vehicle, at 0 and 2 h after the end of hypoxia. Ipsilateral cortical, striatal, and hippocampal damage was quantitated either 5 d later, or at 5 wk after the insult. Treatment with BN 50730 resulted in approximately 60- 80% reduction in ipsilateral tissue loss at both times. Learning and memory were evaluated 5 wk after insult using the Morris Watermaze place navigation task. Severity of cortical and striatal damage correlated significantly with learning and memory deficits. These results support the hypothesis that PAF is a pathogenetic mediator of hypoxic-ischemic damage in the immature brain. Accumulating evidence suggests that PAF mediates its deleterious effects in the immature CNS via multiple mechanisms.

Therapeutic trial in the first three Asian cases of ethylmalonic encephalopathy: response to riboflavin.

Three Korean girls with ethylmalonic encephalopathy, the first Asian cases, were identified. In all three cases, we observed slight improvement in motor functions, cognitive behaviours and chronic mucoid diarrhoea after treatment with riboflavin and/or coenzyme Q10 treatment. The precise pathogenesis of ethylmalonic encephalopathy has not been fully elucidated, but riboflavin treatment may be helpful.

Pentoxifylline attenuates hypoxic-ischemic brain injury in immature rats.

Inflammatory mediators are implicated in the pathogenesis of ischemic injury in immature brain. The phosphodiesterase inhibitor pentoxifylline inhibits production of tumor necrosis factor-alpha and platelet-activating factor. We hypothesized that pentoxifylline treatment would attenuate hypoxic-ischemic brain injury in immature rats. Seven-day-old rats (n = 79) underwent right carotid ligation, followed by hypoxia (FiO2 = 0.08). Rats received pentoxifylline immediately before and again after hypoxia (two doses, 25-150 mg/kg/dose, n = 34), or vehicle (n = 27). In separate experiments, rats received pentoxifylline treatment (40 mg/kg/dose, n = 8), or vehicle (n = 10) immediately and again 3 h after hypoxia-ischemia. Severity of injury was assessed 5 d later by visual evaluation of ipsilateral hemisphere infarction and by measurement of bilateral hemispheric cross-sectional areas. Pentoxifylline pretreatment reduced the incidence of liquefactive cerebral infarction, from 75% in controls to 10% with pentoxifylline, 40 mg/kg/dose (p<0.001, chi2 trend test). Quantification of hemispheric areas confirmed these findings. In contrast, posthypoxic-ischemic treatment with pentoxifylline resulted in only a modest reduction in cortical damage, without an overall reduction in incidence of infarction. Phosphodiesterase inhibition may be an effective strategy to use to decrease the severity of neonatal hypoxic-ischemic brain injury. Pretreatment regimens could be clinically relevant in settings in which an increased risk of cerebral ischemia can be anticipated, such as in infants undergoing surgery to correct congenital heart disease.

Age and seasonal distribution of menarche in Korean girls.

PIP: This paper examines the menarchal age of Korean girls and its monthly distribution to define the possible relationship between menarche and season. Menarchal age is influenced by diverse factors such as hereditary, geography, climate, psychological factors, socioeconomic status, body weight and height, nutritional state, body fat and exercise as well as the presence of chronic illness. In Korea, there is evidence of secular change toward earlier menarchal age, where the average menarchal age was 14.8 in 1952, 14.4 years in 1979, 13.4 years in 1986, and 12.5 years in 1988. A cross-sectional study was conducted from July 1993 to July 1995 among 4237 female middle and high school students, aged 14-20 years, in Ansan, Korea, to obtain data on demographic characteristics, menarchal age, month of menarche, and the menarchal age of the participant's mother. Findings revealed that average menarchal age is 12.5 years for the girls and 15.4 +or- 2.3 years for their mothers. Menarche is most common in August and January (summer), January and December (winter) in decreasing order. Seasonal pattern of menarche may also be related to the psychological factors during school vacation such as relaxation, decrease stress from studies, and/or physical rest.^ieng

The platelet-activating factor antagonist BN 52021 attenuates hypoxic-ischemic brain injury in the immature rat.

Platelet-activating factor (PAF) is overproduced in ischemic brain. Although postischemic PAF antagonist administration protects the mature brain in some models, little is known about the effects of PAF antagonists in the immature brain. We hypothesized that the PAF antagonist BN 52021 would attenuate perinatal cerebral hypoxic-ischemic injury. To elicit focal hypoxic-ischemic brain injury, 7-d-old (P7) rats (n = 111) underwent right carotid ligation, followed by 2.5-3.25 h of hypoxia (fractional concentration of inspired O2 = 0.08). BN 52021 neuroprotection was evaluated in three groups of experiments: 1) 25 mg/kg/dose, 0 and 2 h posthypoxia; 2), 25 mg/kg/dose immediately before and 1 h after hypoxia; and 3) posthypoxia-ischemia treatment with BN 52021 12.5, 25, or 50 mg/kg/dose in 2 doses 0 and 2 h after hypoxia. All experiments included concurrent vehicle-injected controls. To quantitate severity of injury, bilateral regional cross-sectional areas (groups 1 and 2) or hemisphere weights (group 3) were evaluated on P12. Both pre- and posthypoxic treatment with BN 52021 (25 mg/kg/dose, two serial doses) decreased the incidence of cerebral infarction from 90% to about 30% (p < 0.02, Fisher's exact test). Measurement of cross-sectional areas confirmed neuroprotection and indicated some benefit of pre- over posthypoxic-ischemic treatment in hippocampus and cortex. Over the dose range tested, the neuroprotective effect of BN 52021 administration was not dose-dependent. In contrast, BN 52021 did not attenuate N-methyl-D-aspartate-induced hippocampal excitotoxic injury in P7 rats. Either prophylactic or "rescue" administration of PAF antagonists decreases the incidence and severity of brain injury associated with an episode of perinatal cerebral hypoxia-ischemia.